Instil Bio 8-K: Administrative Update, Confirms Emerging Growth Status
Ticker: TIL · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1789769
| Field | Detail |
|---|---|
| Company | Instil Bio, INC. (TIL) |
| Form Type | 8-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.000001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, 8-K, corporate-governance
TL;DR
**Instil Bio filed a routine 8-K, mostly administrative, no major news for traders.**
AI Summary
Instil Bio, Inc. filed an 8-K on January 18, 2024, reporting an 'Other Event' that occurred on January 17, 2024. This filing primarily updates administrative information, confirming the company's status as an 'emerging growth company' and its common stock, with a $0.000001 par value, is traded on The Nasdaq Stock Market LLC under the symbol TIL. For investors, this filing is largely administrative and doesn't signal any immediate operational or financial changes, meaning it has minimal direct impact on the stock's valuation or future prospects.
Why It Matters
This filing is mostly administrative, confirming Instil Bio's status and listing details, and does not contain new material information that would significantly impact investment decisions.
Risk Assessment
Risk Level: low — The filing contains no new material financial or operational information that would introduce new risks or change existing ones.
Analyst Insight
A smart investor would recognize this as a routine, non-material filing and would not make any immediate investment decisions based solely on this information. Further research into the company's operational and financial performance would be necessary.
Key Numbers
- $0.000001 — par value per share (the nominal value of Instil Bio's common stock)
Key Players & Entities
- Instil Bio, Inc. (company) — the registrant filing the 8-K
- The Nasdaq Stock Market LLC (company) — the exchange where Instil Bio's common stock is registered
- $0.000001 (dollar_amount) — par value of Instil Bio's common stock
Forward-Looking Statements
- Instil Bio's stock price will remain unaffected by this specific 8-K filing. (Instil Bio, Inc.) — high confidence, target: 2024-01-19
FAQ
What is the purpose of this 8-K filing by Instil Bio, Inc.?
This 8-K filing by Instil Bio, Inc. is categorized under 'Other Events' and primarily serves to update administrative information, such as confirming its status as an 'emerging growth company' and detailing its common stock listing on The Nasdaq Stock Market LLC.
When was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was January 17, 2024.
What is the trading symbol for Instil Bio, Inc.'s common stock?
The trading symbol for Instil Bio, Inc.'s common stock is TIL, and it is registered on The Nasdaq Stock Market LLC.
What is the par value of Instil Bio, Inc.'s common stock?
The par value of Instil Bio, Inc.'s common stock is $0.000001 per share.
Is Instil Bio, Inc. considered an 'emerging growth company' according to this filing?
Yes, Instil Bio, Inc. has indicated by check mark in the filing that it is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2024-01-18 07:01:42
Key Financial Figures
- $0.000001 — ange on which registered Common Stock, $0.000001 par value TIL The Nasdaq Stock Market L
Filing Documents
- til-20240117.htm (8-K) — 31KB
- 0001789769-24-000020.txt ( ) — 157KB
- til-20240117.xsd (EX-101.SCH) — 2KB
- til-20240117_lab.xml (EX-101.LAB) — 24KB
- til-20240117_pre.xml (EX-101.PRE) — 13KB
- til-20240117_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. As previously disclosed, Instil Bio, Inc. (the "Company") has entered into an agreement with a collaborator to conduct preclinical manufacturing feasibility studies in the ITIL-306 program with the aim of enrolling patients in investigator-initiated (IIT) clinical trials. At this time, the Company is providing no guidance with respect to the timing of any data readout with respect to its ITIL-306 program, including any IIT studies. Cautionary Note Regarding Forward-Looking Statements This Current Report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the aims of the collaboration and the Company's expectations related thereto, which are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including the Company's ability to achieve the aims of the collaboration, including to successfully complete manufacturing feasibility studies and enroll patients into IIT clinical trials, and other risks and uncertainties affecting the Company and its ITIL-306 program, including those discussed in the section titled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and in subsequent filings with the SEC. Forward-looking statements in this Current Report are made as of the date of this Current Report and the Company undertakes no duty to update any such statements unless required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Instil Bio, Inc. Dated: January 18, 2024 By: /s/ Sandeep Laumas, M.D. Sandeep Laumas, M.D. Chief Financial Officer and Chief Business Officer (Principal Financial Officer and Principal Accounting Officer)